BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25911911)

  • 1. [Hepatic parenchimatous damage and perfusion disturbance in the progression of nonalcoholic fatty liver disease].
    Dudanova OP; Belavina IA
    Eksp Klin Gastroenterol; 2014; (8):41-5. PubMed ID: 25911911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Splenoportal blood flow with nonalcoholic fatty liver disease].
    Dudanova OP; Belavina IA
    Eksp Klin Gastroenterol; 2010; (5):14-8. PubMed ID: 20731130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.
    Nasr P; Hilliges A; Thorelius L; Kechagias S; Ekstedt M
    Scand J Gastroenterol; 2016 Sep; 51(9):1126-32. PubMed ID: 27161854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.
    Hirooka M; Koizumi Y; Miyake T; Ochi H; Tokumoto Y; Tada F; Matsuura B; Abe M; Hiasa Y
    Radiology; 2015 Feb; 274(2):597-604. PubMed ID: 25302830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
    Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
    Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
    Chalasani N; Abdelmalek MF; Garcia-Tsao G; Vuppalanchi R; Alkhouri N; Rinella M; Noureddin M; Pyko M; Shiffman M; Sanyal A; Allgood A; Shlevin H; Horton R; Zomer E; Irish W; Goodman Z; Harrison SA; Traber PG;
    Gastroenterology; 2020 Apr; 158(5):1334-1345.e5. PubMed ID: 31812510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases.
    Ochi H; Hirooka M; Koizumi Y; Miyake T; Tokumoto Y; Soga Y; Tada F; Abe M; Hiasa Y; Onji M
    Hepatology; 2012 Oct; 56(4):1271-8. PubMed ID: 22488593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease.
    Khov N; Sharma A; Riley TR
    World J Gastroenterol; 2014 Jun; 20(22):6821-5. PubMed ID: 24944472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease.
    Ebert T; Linder N; Schaudinn A; Busse H; Berger J; Lichtinghagen R; Keim V; Wiegand J; Karlas T
    Endocrine; 2017 Nov; 58(2):246-252. PubMed ID: 28914407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease.
    Mann JP; De Vito R; Mosca A; Alisi A; Armstrong MJ; Raponi M; Baumann U; Nobili V
    Hepatology; 2016 Mar; 63(3):745-53. PubMed ID: 26638195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.
    Baffy G
    Dig Dis Sci; 2018 Mar; 63(3):563-576. PubMed ID: 29368124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver histology and diffusion-weighted MRI in children with nonalcoholic fatty liver disease: A MAGNET study.
    Manning P; Murphy P; Wang K; Hooker J; Wolfson T; Middleton MS; Newton KP; Behling C; Awai HI; Durelle J; Paiz MN; Angeles JE; De La Pena D; McCutchan JA; Schwimmer JB; Sirlin CB
    J Magn Reson Imaging; 2017 Oct; 46(4):1149-1158. PubMed ID: 28225568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive assessment of liver steatosis, fibrosis and inflammation in chronic hepatitis C virus infection.
    Schneider AR; Teuber G; Kriener S; Caspary WF
    Liver Int; 2005 Dec; 25(6):1150-5. PubMed ID: 16343065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver hemodynamic patterns in nonalcoholic steatosis: Doppler ultrasonography and histological evaluation.
    Gonçalves Dos Reis Monteiro ML; Ferreira De Almeida E Borges V; Machado De Alcântara T; Borges De Araújo L; De Fátima Pinheiro C; Lemos Debs Diniz A
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):19-29. PubMed ID: 26887796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
    Harrison SA; Abdelmalek MF; Caldwell S; Shiffman ML; Diehl AM; Ghalib R; Lawitz EJ; Rockey DC; Schall RA; Jia C; McColgan BJ; McHutchison JG; Subramanian GM; Myers RP; Younossi Z; Ratziu V; Muir AJ; Afdhal NH; Goodman Z; Bosch J; Sanyal AJ;
    Gastroenterology; 2018 Oct; 155(4):1140-1153. PubMed ID: 29990488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients.
    Selvakumar PK; Kabbany MN; Lopez R; Tozzi G; Alisi A; Alkhouri N; Nobili V
    Dig Liver Dis; 2016 Aug; 48(8):909-13. PubMed ID: 27198736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.